This study is enrolling adolescents ages 13 to 17 who have been diagnosed with schizophrenia and have not previously received the study medication. The purpose of the study is to evaluate the long-term safety and tolerability of an investigational oral medication taken once daily. Participants will complete a brief screening period followed by approximately 26 weeks of treatment, with regular clinic visits for health and symptom monitoring while continuing routine outpatient care under caregiver supervision.